Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia

British Journal of Clinical Pharmacology

Volumn 71, Issue 2, 2011, Pages 199-206

  Kim, Dong Wook ^a   Tan, Eugene Y ^b   Jin, Yu ^b   Park, Sahee ^a   Hayes, Michael ^b   Demirhan, Eren ^b   Schran, Horst ^b   Wang, Yanfeng ^b  

^a The Catholic University of Korea   (South Korea)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acetaminophen; CML; Imatinib; Korean; Paracetamol; Pharmacokinetics

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; IMATINIB; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARACETAMOL SULFATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOUTH KOREA; URINARY EXCRETION;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 78650994740     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03810.x     Document Type: Article

References (30)

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
2. Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest 2005; 23: 274-80.
3. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 444: 879-94.
4. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-42.
5. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, Seiberling M. Pharmacokinetic interaction between ketoconazole and imatinib in healthy subjects. Cancer Chemother Pharmacol 2004; 54: 290-4.
6. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004; 53: 102-6.
7. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004; 24: 1508-14.
8. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76: 323-9.
9. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005; 23: 9359-68.
10. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R, Fischer T. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukemia. Br J Cancer 2003; 89: 1855-9.
11. Wang Y, Zhou L, Dutriex C, Leroy E, Yin Q, Sethuraman V, Riviere GJ, Yin OQP, Schran H, Shen ZX. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukemia. Br J Clin Pharmacol 2008; 65: 885-92.
12. Bessems JGM, Vermeulen NPE. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanism, analogues and protective approaches. Crit Rev Toxicol 2001; 31: 55-138.
13. Prescott LF, Critchley JAJH, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. Br J Clin Pharmacol 1981; 12: 149-53.
14. Haderslev KV, Sonne J, Poulsen HE, Loft S. Paracetamol metabolism in patients with ulcerative colitis. Br J Clin Pharmacol 1998; 46: 513-6.
15. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45: 1563-9.
16. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochrome P450IIE1 and P450IA2. Arch Biochem Biophys 1989; 271: 270-83.
17. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Keiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther 1974; 16: 676-84.
18. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High throughput quantification of the anti-leukaemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 768: 325-40.
19. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. March 2003. Available at (last accessed 4 August 2010).
20. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 26 July 2001. Available at (last accessed 4 August 2010).
21. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Am MB, Peng B, Gross G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005; 33: 1503-12.
22. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-8.
23. Zhao Y, Ruan ZR, Yuan H, Zhou Y, Ding DY. Pharmacokinetics and bioavailability of tablet PVP-acetaminophen in healthy volunteers after a single oral dose study. Chin J Clin Pharmacol 1995; 11: 229-33.
24. Yin OQP, Tomlinson B, Chow AHL, Chow MSS. Pharmacokinetics of acetaminophen in Hong Kong Chinese subjects. Int J Pharm 2001; 222: 305-8.
25. Sahajwalla CG, Ayres JW. Multiple-dose acetaminophen pharmacokinetics. J Pharm Sci 1991; 80: 855-60.
26. Osborne NJ, Tonkin AL, Miners JO. Interethnic differences in drug glucuronidation: a comparison of paracetamol in Caucasians and Chinese. Br J Clin Pharmacol 1991; 32: 765-7.
27. Kamali F. The effect of probenecid on paracetamol metabolism and pharmacokinetics. Eur J Clin Pharmacol 1993; 45: 551-3.
28. Mucklow JC, Fraser HS, Bulpitt CJ, Kahn C, Mould G, Dolley CT. Environmental factors affecting paracetamol metabolism in London factory and office workers. Br J Clin Pharmacol 1980; 10: 67-74.
29. Miners JO, Penhall R, Robson RA, Birkett DJ. Comparison of paracetamol metabolism in young adult and elderly males. Eur J Clin Pharmacol 1988; 35: 157-60.
30. Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1973; 1: 553-67.